The arrival of gene therapy has changed the counseling and management for patients with inherited retinal dystrophies, creating the possibility of halting progression and even potentially improving vision. Voretigene neparvovec-rzyl gene therapy has been FDA approved for RPE65 mutation-associated retinal dystrophy and many other interventional gene therapy clinical trials are currently under way. However, it is necessary for patients to complete genetic testing to determine if they may be candidates for current gene therapy or clinical trials.  This interactive lecture and workshop walks through the entire process for genetic testing: clinical determination of genetic eye disease, sample collection, analysis of genetic test results, interpretation of results within clinical context, and patient counseling.  Attendees will participate in simulated patient cases, starting with case history and interpretation of exam findings to determine eligibility for genetic testing. Participants will be guided through hands-on saliva sample collection (if safety allows), completion of genetic testing program eligibility and test requisition forms, completion of patient consent forms, interpretation of provided genetic test result printouts, discussion of patient counseling considerations, and determination of patient eligibility for clinical trials and gene therapy. Participants will receive clinical pearls for successful genetic testing.   It is recommended that attendees enrolling in this workshop have a working understanding of the basics of genetic inheritance patterns and familiarity with inherited retinal dystrophies.

Course Code:



Rachelle Lin, O.D.



AOA Expiration Date:


Related News

Constant presence: Alliance builds reputation for patient safety advocacy

Founded five years ago, the Health Care Alliance for Patient Safety (HCAPS) is making good on its mission to advocate for patient safety and protect the fundamental doctor-patient relationship. The alliance’s advocacy will be recognized with the AOA’s Apollo Award during a ceremony at the 2023 Optometry’s Meeting® June 21-24.

What defines the value of care we provide?

Health and vision plans have not adapted and grown with the care we deliver but hold back optometry’s momentum.

How to speak the universal language of care

How to create a bilingual and culturally sensitive practice, why it matters to patients and how it can set you apart from the competition.